As the US prepares to transition to a commercial market for COVID-19 vaccines and treatments in 2023, Pfizer Inc./BioNTech SE and Moderna, Inc. are predicting uptake of their vaccines will align with flu vaccines at roughly 50% of adults.
But the current COVID-19 bivalent booster rate in adults is only around 15%, according to the Centers for Disease Control...







